Revvity

3,109 Total Employees
Year Founded: 2023
View Website

Revvity Company Stability & Growth

Updated on February 07, 2026

This page was generated by Built In using publicly available information and AI-based analysis of common questions about the company. It has not been reviewed or approved by the company.

What's the stability & growth outlook for Revvity?

Strengths in niche leadership, global reach, and partnership‑driven execution are accompanied by margin pressure, a modest organic growth pace, and smaller overall scale versus industry leaders. Together, these dynamics suggest a resilient specialist with durable positions in chosen categories and a measured growth and profitability profile at the company level.
Positive Themes About Revvity
  • Strong Market Position & Advantage: Revvity is a clear leader in newborn screening and preclinical in vivo imaging, with EUROIMMUN recognized in autoimmune diagnostics and T‑SPOT.TB a major IGRA alternative. A long legacy, large installed base across 100+ countries, and high‑profile programs like the Genomics England newborn study reinforce category authority.
  • Resilient & Sustainable Growth: Revenue expanded in 2025 with steady low single‑digit organic growth, led by Diagnostics outpacing Life Sciences. A broad global footprint across 160+ countries and recurring clinical workflows support durable, incremental expansion.
  • Strategic Partnerships: Collaborations and tenders—such as newborn genomics initiatives and alliances with sequencing and mass‑spec partners—bolster positioning in sample‑to‑answer workflows. Recent automation clearances and investment in a Center of Excellence indicate continued ecosystem strengthening.
Considerations About Revvity
  • Declining Profitability: Margins compressed year over year in 2025, with GAAP and segment adjusted margins down even as revenue rose. Market updates highlighted margin pressure as a key watch‑item despite EPS improvement.
  • Stagnant Revenue: Organic growth remains modest, with Life Sciences essentially flat and management guiding to low single‑digit expansion for 2026. This points to steady rather than rapid top‑line acceleration.
  • Weak Market Position & Pricing Challenges: At the overall market level, the company is mid‑scale versus giants like Thermo Fisher, Danaher, and Roche and competes selectively rather than end‑to‑end. Mixed investor reactions to guidance and the scale gap indicate it is not the broad market leader across tools and diagnostics.
NEW
What does AI tell candidates about your employer brand?
Get your free AI reputation report today.
See AI Report
AI Report
AI Report
The insights on this page are generated by submitting structured prompts to some of the most popular large language models (“LLMs”) and summarizing recurring themes from the responses. Because the insights are generated using AI, they may contain errors. The insights do not necessarily reflect internal data, employee interviews, or verified company information. They may be influenced by incomplete, outdated, or inaccurate data, and may vary across LLM providers. These insights are intended for informational purposes only and should not be interpreted as a factual or definitive assessment of a company's reputation. Built In makes no representations or warranties regarding the accuracy, completeness, or reliability of this information, and disclaims any liability for any actions taken based on this information. If you are a representative of this company, and would like this page to be removed, you may contact us via this form.
View All 83 Jobs at Revvity
Is This Your Company? Claim Profile